{"schema_version":"secwatch.filing_event.v1","accession":"0001129928-26-000070","form_type":"8-K","ticker":"ONCY","cik":"0001129928","company_name":"ONCOLYTICS BIOTECH INC","filed_at":"2026-10-13T12:10:56+00:00","discovered_at":"2026-10-13T12:15:00.275621+00:00","generated_at":"2026-10-13T12:15:07.815174+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Oncolytics says new pelareorep method-of-use patents extend IP protection into late 2040s","bullets":["New method-of-use patent covering pelareorep as a cancer immunotherapy issued in several countries; corresponding U.S. patent expected in the near term.","Existing manufacturing patent protection runs through 2044; company targets extension into the late 2040s via new patents.","Three patent application families pending, including multiple method-of-use filings covering pelareorep with immunotherapies and targeted therapies.","Company expects to convert one pending application to a USPTO Track One prioritized examination this quarter, targeting final disposition in ~12 months.","Working with an academic partner on 'next generation' modified pelareorep; a new composition of matter patent could add up to 20 years from filing, CEO Jared Kelly said."],"urls":{"canonical":"https://secwatch.observer/filing/0001129928-26-000070","json":"https://secwatch.observer/filing/0001129928-26-000070.json","markdown":"https://secwatch.observer/filing/0001129928-26-000070.md","text":"https://secwatch.observer/filing/0001129928-26-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000070/0001129928-26-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000070/oncy-20261012.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-13T12:15:07.815174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}